Company intelligence / Profile preview
Meissa Vaccines
Redwood City (previously South San Francisco), California, United Statesmeissavaccines.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Meissa's intranasal pediatric RSV vaccine candidate (MV-012-968) demonstrated high immunogenicity with an outstanding safety profile in a Phase 1c study in RSV seronegative infants and young children. All RSV-naïve infants and toddlers demonstrated a vaccine response to the highest dose tested. For their COVID-19 vaccine candidate, early clinical data showed the highest dose triggered similar nasal antibody levels to natural immunity[3][6].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Live attenuated vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Exothera S.A. (manufacturing agreement)
Beyond the preview
Go deeper on Meissa Vaccines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Meissa Vaccines.